Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

POS - Form 8-K-a one-year extension of the Company’s current stock buyback program

Company: Oramed Pharmaceuticals Inc. Date: 2025-05-22 Language: Hebrew (modern) Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

# **FORM 8-K**

### **CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 21, 2025**

# **ORAMED PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

| DELAWARE                                                        | 001-35813                | 98-0376008          |
|-----------------------------------------------------------------|--------------------------|---------------------|
| (State or Other Jurisdiction                                    | (Commission File Number) | (IRS Employer       |
| of Incorporation)                                               |                          | Identification No.) |
| 1185 Avenue of the Americas, Third Floor,<br>New York, New York |                          | 10036               |
| (Address of Principal Executive Offices)                        |                          | (Zip Code)          |

**844-967-2633**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class             | Trading symbol | Name of each exchange on which registered |
|---------------------------------|----------------|-------------------------------------------|
| Common Stock, par value \$0.012 | ORMP           | The Nasdaq Capital Market,                |
|                                 |                | Tel Aviv Stock Exchange                   |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

### **Item 8.01 Other Events**

On May 21, 2025, Oramed Pharmaceuticals Inc. (the "Company") announced that its Board of Directors authorized a one-year extension of the Company's current stock buyback program, which was set to expire in June 2025, pursuant to which the Company may, from time to time, purchase up to \$20,000,000 in maximum value of its common stock, of which, as of May 21, 2025, \$2,494,000 in value of shares has been repurchased. The renewed stock buyback program (the "Stock Buy Back Program") retains the same maximum value of the Company's common stock available for repurchase. Share repurchases may be executed through various means, including, without limitation, open market transactions, privately negotiated transactions or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The Stock Buy Back Program does not obligate the Company to purchase any shares and expires in June 2026. The authorization for the Stock Buy Back Program may be terminated, increased or decreased by the Company's Board of Directors in its discretion at any time.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **ORAMED PHARMACEUTICALS INC.**

By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO

May 21, 2025

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.